MX2012007318A - Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia. - Google Patents
Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.Info
- Publication number
- MX2012007318A MX2012007318A MX2012007318A MX2012007318A MX2012007318A MX 2012007318 A MX2012007318 A MX 2012007318A MX 2012007318 A MX2012007318 A MX 2012007318A MX 2012007318 A MX2012007318 A MX 2012007318A MX 2012007318 A MX2012007318 A MX 2012007318A
- Authority
- MX
- Mexico
- Prior art keywords
- sirpî
- constant region
- antibody
- soluble
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona con las proteínas de enlace SIRPa solubles, para usarlas como un medicamento, en particular para la prevención o el tratamiento de trastornos autoinmunes e inflamatorios, por ejemplo asma alérgico y enfermedades inflamatorias del intestino. La invención más específicamente se relaciona con una proteína de enlace SIRPa soluble que comprende un complejo de dos heterodímeros, en donde cada heterodímero esencialmente consiste en: (i) un primer polipéptido de cadena simple monovalente que comprende un primer dominio de enlace SIRPa fusionado a la parte de terminal N de una región constante de cadena pesada de un anticuerpo; y (ii) un segundo polipéptido de cadena simple monovalente que comprende un segundo dominio de enlace SIRPa fusionado a la parte de la terminal N de una región constante de cadena ligera CL de un anticuerpo. La invención, además, se relaciona con la proteína parecida a anticuerpo que se enlaza a SIRPa, soluble, como se muestra en la Figura 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28900709P | 2009-12-22 | 2009-12-22 | |
| PCT/EP2010/070355 WO2011076781A1 (en) | 2009-12-22 | 2010-12-21 | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012007318A true MX2012007318A (es) | 2012-07-20 |
Family
ID=43706449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007318A MX2012007318A (es) | 2009-12-22 | 2010-12-21 | Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130011401A1 (es) |
| EP (1) | EP2516458A1 (es) |
| JP (1) | JP2013514795A (es) |
| KR (1) | KR20120107122A (es) |
| CN (1) | CN102939303A (es) |
| AR (1) | AR079701A1 (es) |
| AU (1) | AU2010334974A1 (es) |
| BR (1) | BR112012017164A2 (es) |
| CA (1) | CA2785139A1 (es) |
| MX (1) | MX2012007318A (es) |
| TW (1) | TW201130511A (es) |
| UY (1) | UY33132A (es) |
| WO (1) | WO2011076781A1 (es) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013014789A (es) * | 2011-06-16 | 2014-01-20 | Novartis Ag | Proteinas solubles para utilizarse como productos terapeuticos. |
| US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| TWI593708B (zh) | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
| AU2013353763B2 (en) * | 2012-12-03 | 2018-09-13 | Novimmune S.A. | Anti-CD47 antibodies and methods of use thereof |
| SMT201900623T1 (it) | 2012-12-17 | 2020-01-14 | Trillium Therapeutics Inc | Trattamento di cellule di malattia cd47+ con fusioni sirp alpha-fc |
| WO2014121093A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| EP2968536B1 (en) * | 2013-03-13 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| KR102215405B1 (ko) | 2013-03-15 | 2021-02-10 | 암젠 인크 | 인간 pac1 항체 |
| CN103204944B (zh) * | 2013-03-26 | 2014-05-28 | 江苏健德生物药业有限公司 | 用于治疗糖尿病的长效免疫融合蛋白 |
| CN103893743B (zh) * | 2014-04-10 | 2016-01-20 | 武汉大学 | 生长分化因子1（gdf1）基因在冠状动脉粥样硬化性心脏病中的功能和应用 |
| CN103898189B (zh) * | 2014-04-10 | 2015-10-28 | 武汉大学 | 信号调节蛋白α（SHSP-1）基因在心肌梗死中的应用 |
| NO2776305T3 (es) | 2014-04-23 | 2018-01-27 | ||
| EP3164417A1 (en) | 2014-07-01 | 2017-05-10 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| US10087257B2 (en) | 2014-08-08 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | SIRP alpha-antibody fusion proteins |
| CN113621075B (zh) * | 2014-08-08 | 2024-09-20 | Alx肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
| JP6956631B2 (ja) | 2014-09-15 | 2021-11-02 | アムジェン インコーポレイテッド | 二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用 |
| BR122024000360A2 (pt) * | 2014-09-19 | 2024-02-27 | City Of Hope | Molécula de ácido nucleico, população de células t humanas transduzidas por um vetor que compreende um cassete de expressão que codifica um receptor de antígeno quimérico e seu uso |
| WO2016100788A1 (en) | 2014-12-19 | 2016-06-23 | Alkermes, Inc. | Single chain fc fusion proteins |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| GB201506402D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| TWI737614B (zh) | 2015-06-11 | 2021-09-01 | 博錸生技股份有限公司 | 已編碼微載體及其製造方法以及用以進行多工分析之包含該等已編碼微載體之套件 |
| IL302491A (en) | 2015-08-07 | 2023-06-01 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| EA034582B1 (ru) * | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Конструкции варианта sirp-альфа и их применение |
| AU2016310348B2 (en) | 2015-08-26 | 2023-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist |
| EP3390447A1 (en) | 2015-12-15 | 2018-10-24 | Amgen Inc. | Pacap antibodies and uses thereof |
| JP7261379B2 (ja) | 2016-06-20 | 2023-04-20 | カイマブ・リミテッド | 抗ｐｄ－ｌ１抗体 |
| AU2017291321B2 (en) | 2016-06-22 | 2020-06-18 | Alkermes, Inc. | Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties |
| WO2018081897A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| IL268731B2 (en) * | 2017-02-17 | 2025-07-01 | Ose Immunotherapeutics | New uses of anti-SIRPG antibodies |
| CN111448210B (zh) | 2017-07-26 | 2024-05-14 | 四十七公司 | 抗SIRP-α抗体及相关方法 |
| MX2020001309A (es) | 2017-08-02 | 2020-08-20 | Phanes Therapeutics Inc | Anticuerpos anti-cd47 y sus usos. |
| CN111051350B (zh) * | 2017-09-07 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | 包含信号调节蛋白α的免疫缀合物 |
| EP3737699A1 (en) | 2018-01-12 | 2020-11-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
| CN112105632A (zh) | 2018-01-24 | 2020-12-18 | 北京智康博药肿瘤医学研究有限公司 | 细胞因子融合蛋白 |
| WO2020113403A1 (en) * | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| CN112912103A (zh) * | 2018-05-21 | 2021-06-04 | 拜奥普罗塞亚科技有限责任公司 | 多价蛋白质复合物 |
| US11634490B2 (en) | 2018-06-15 | 2023-04-25 | Accurus Biosciences, Inc. | Blocking antibodies against CD47 and methods of use thereof |
| KR20250079073A (ko) | 2018-07-10 | 2025-06-04 | 고쿠리츠다이가쿠호진 고베다이가쿠 | 항 SIRPα 항체 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN110540589B (zh) * | 2019-01-08 | 2021-07-20 | 西南大学 | 一种多肽、多肽修饰的脂质载体及应用 |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| PH12021553256A1 (en) | 2019-06-25 | 2022-08-08 | Gilead Sciences Inc | Flt3l-fc fusion proteins and methods of use |
| PL4045083T3 (pl) | 2019-10-18 | 2024-05-13 | Forty Seven, Inc. | Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej |
| EP4052040A1 (en) | 2019-10-31 | 2022-09-07 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| JP2023502441A (ja) | 2019-11-25 | 2023-01-24 | アルカームス インコーポレーテッド | 置換大環状化合物および関連する治療方法 |
| SI4081305T1 (sl) | 2019-12-24 | 2025-03-31 | Carna Biosciences, Inc. | Spojine, ki modulirajo diacilglicerol kinazo |
| CN115087488A (zh) | 2020-02-14 | 2022-09-20 | 震动疗法股份有限公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CA3216908A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| KR20240023628A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US20240165229A1 (en) | 2021-06-29 | 2024-05-23 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CR20240173A (es) | 2021-10-29 | 2024-06-20 | Gilead Sciences Inc | Compuestos de cd73 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| HUE069263T2 (hu) | 2022-03-17 | 2025-02-28 | Gilead Sciences Inc | Ikarosz cink-ujj család degradálói és azok alkalmazása |
| WO2023183890A1 (en) * | 2022-03-24 | 2023-09-28 | Bitterroot Bio, Inc. | Multivalent sirp-alpha fusion polypeptides |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| IL316058A (en) | 2022-04-21 | 2024-11-01 | Gilead Sciences Inc | Compounds modulate KRAS G12D |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| CA2080226C (en) * | 1991-02-08 | 2004-05-04 | Gary A. Beaudry | Cd4-gamma2 and cd4-igg2 chimeras |
| US7070991B2 (en) * | 1991-02-08 | 2006-07-04 | Progenics Pharmaceuticals, Inc. | Cells expressing a CD4-IgG2 chimeric heterotetramer |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DE19709861C2 (de) | 1997-03-11 | 1999-04-01 | Vitcon Projektconsult Gmbh | Einrichtung zur Ablation von Material mit Hilfe von Laserstrahlung |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| EP2275541B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP2295079A3 (en) | 1999-12-23 | 2011-03-23 | ZymoGenetics, L.L.C. | Method for treating inflammation |
| EP1522590B1 (en) | 2000-06-28 | 2009-08-26 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
| US20050142139A1 (en) * | 2003-03-21 | 2005-06-30 | Norbert Schulke | CD4-IgG2 formulations |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| US8377448B2 (en) * | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP2027151A2 (en) * | 2006-05-15 | 2009-02-25 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| WO2009046541A1 (en) | 2007-10-11 | 2009-04-16 | University Health Network | MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR |
-
2010
- 2010-12-21 TW TW099145049A patent/TW201130511A/zh unknown
- 2010-12-21 MX MX2012007318A patent/MX2012007318A/es not_active Application Discontinuation
- 2010-12-21 BR BR112012017164A patent/BR112012017164A2/pt not_active IP Right Cessation
- 2010-12-21 WO PCT/EP2010/070355 patent/WO2011076781A1/en active Application Filing
- 2010-12-21 CN CN2010800644263A patent/CN102939303A/zh active Pending
- 2010-12-21 US US13/517,989 patent/US20130011401A1/en not_active Abandoned
- 2010-12-21 AU AU2010334974A patent/AU2010334974A1/en not_active Abandoned
- 2010-12-21 EP EP10795387A patent/EP2516458A1/en not_active Withdrawn
- 2010-12-21 KR KR1020127019187A patent/KR20120107122A/ko not_active Withdrawn
- 2010-12-21 JP JP2012545290A patent/JP2013514795A/ja active Pending
- 2010-12-21 CA CA2785139A patent/CA2785139A1/en not_active Abandoned
- 2010-12-22 AR ARP100104886A patent/AR079701A1/es unknown
- 2010-12-22 UY UY33132A patent/UY33132A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR079701A1 (es) | 2012-02-15 |
| EP2516458A1 (en) | 2012-10-31 |
| CN102939303A (zh) | 2013-02-20 |
| AU2010334974A1 (en) | 2012-07-12 |
| CA2785139A1 (en) | 2011-06-30 |
| US20130011401A1 (en) | 2013-01-10 |
| BR112012017164A2 (pt) | 2019-09-24 |
| KR20120107122A (ko) | 2012-09-28 |
| TW201130511A (en) | 2011-09-16 |
| JP2013514795A (ja) | 2013-05-02 |
| WO2011076781A1 (en) | 2011-06-30 |
| UY33132A (es) | 2011-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012007318A (es) | Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia. | |
| PH12021550802A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| WO2014100439A3 (en) | B7-h4 specific antibodies, and compositions and methods of use thereof | |
| WO2012075184A3 (en) | Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof | |
| UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
| EA201490020A1 (ru) | Растворимые белки для применения в качестве терапевтических средств | |
| NZ592516A (en) | Antibodies to il-6 and use thereof | |
| EA201492253A1 (ru) | Конструкторы, связывающиеся с ron, и способы их использования | |
| PH12014502527B1 (en) | St2 antigen binding proteins | |
| UA104663C2 (xx) | Антитіло, що зв'язує cd127$антитело, связывающее cd127 | |
| PH12012502193A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| EA201201047A1 (ru) | Способы и композиции, в которых применяют слитые полипептиды fgf 23 | |
| JO2828B1 (en) | Anti-Hepsidine antibodies and their uses | |
| MY165273A (en) | Anti-cd48 antibodies and uses thereof | |
| EA201291138A1 (ru) | Способы, композиции и наборы для лечения нарушений, связанных с минерализацией матрикса | |
| NZ599875A (en) | Human il-23 antigen binding proteins | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| EA201070730A1 (ru) | Гуманизированные антитела, специфичные к фактору фон виллебранда | |
| GB201201314D0 (en) | Composition | |
| TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| HK1254862A1 (zh) | 激活瘦素受体的抗原结合蛋白 | |
| TW200745163A (en) | Peptides that block the binding of IgG to FcRn | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
| HK1208474A1 (en) | Antigen binding proteins that bind egfr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |